To the Editor.
—Both in their editorial entitled "Cysticercosis: An Old Scourge Revisited" (Archives 1982; 39:533) and in their article entitled "CNS Cysticercosis" (Archives 1982;39:540-544), Grisolia and Wiederholt commented that no specific medical therapy is available for neurocysticercosis. The accompanying article by McCormick et al (Archives 1982; 39:534-539) mentioned animal but not human studies using the acylated isoquinoline-pirazine compound praziquantel in the treatment of that condition, stating that "the ultimate role of this drug is yet to be defined." We wonder whether the authors of these three articles continue to believe there is no specific treatment for neurocysticercosis in light of the recently reported experience with praziquantel treatment of human diseases.1-4 In their latest study of 31 cases of neurocysticercosis, Botero and Castano4 reported a drop in mortality with praziquantel therapy, to 3.2% from an earlier range of 50% to 80%. A trial of praziquantel therapy may therefore be
Friedman J, Mates S. Praziquantel Therapy for Cysticercosis. Arch Neurol. 1983;40(4):257. doi:10.1001/archneur.1983.04050040087022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: